Search

everythinglearnresearchcommunity

for

Search:↓

People are excited about a new hair loss treatment, PP405, and some suggest using Twitter to increase its visibility. Current treatments mentioned include finasteride, minoxidil, and dutasteride, but skepticism remains about the effectiveness of new treatments.

GT20026 is discussed as a potential treatment for hair loss that targets androgen receptors without affecting hormone levels, but it may not promote significant regrowth. It is expected to be available by 2028, with other treatments like Breezula and Clascoterone also mentioned.

Pelage is moving to Phase III clinical trials for PP405, a hair loss treatment, with results to be presented at a medical meeting. Users express skepticism and hope, comparing it to existing treatments like Minoxidil and finasteride, while discussing the potential for new hair growth in previously bald areas.

PP405 is discussed as a potential adjunct therapy for hair loss, with skepticism about its effectiveness and trial results. Users mention combining it with finasteride and minoxidil for better results, while others debate the root causes of hair loss and the limitations of current treatments.

PP405 (Everychem 3HP) may help with hair regrowth, with mixed user experiences. Users often combine it with minoxidil and finasteride, but there are concerns about its efficacy and side effects.

The conversation discusses the potential benefits and risks of participating in the PP405 hair loss trials, emphasizing that those using Minoxidil or finasteride are less likely to be accepted. Participants are interested in the trial as it offers hope for effective treatment without the side effects associated with current medications.

KX826 shows promise as a hair loss treatment with a 10% increase in hair count, but concerns about Kintor's marketing practices and the systemic effects of treatments like GT20029 and RU58841 remain. Users express skepticism and hope, with some preferring traditional treatments like finasteride and minoxidil.

The user is seeking alternatives to propylene glycol and glycerin for mixing with RU58841 due to allergies and greasiness. Suggestions include reducing glycerin and considering stemoxydine as a solvent.

PP405 is a promising hair growth stimulant but not a cure for advanced hair loss, as it may only help dormant follicles. Treatments like Minoxidil, Finasteride, and Dutasteride are discussed, with emphasis on early intervention for effectiveness.

Concerns about the potential high cost of new hair loss treatments, pp405 and gt20029, were discussed, with some users willing to pay a premium if they are effective. Alternatives like finasteride and minoxidil are mentioned as current, more affordable options, and there is speculation about future generic versions and black market availability.

User experienced hair loss after surgery and was diagnosed with TE. The doctor recommended PRP therapy, Finasteride, Anatrix pro Hair Serum, a multivitamin, and a lotion and shampoo containing Zinc Pyrithione.

PP405 is a potential hair loss treatment, but its safety and effectiveness are uncertain. Users advise caution and suggest waiting for more data before purchasing unverified versions.

Hair loss treatments like spironolactone often require lifelong use to maintain results. Stopping the medication can lead to increased testosterone levels and potential hair loss.

The conversation discusses the differences between PG/Ethanol and KB solutions for RU58841 application, focusing on potential scalp irritation. KB solution is suggested for those allergic to PG, though both contain ethanol which can dry the scalp.

People are discussing obtaining and testing PP405 for hair loss treatment, with concerns about its purity and effectiveness. Some are considering delaying hair transplants, while others suggest using existing treatments like finasteride and minoxidil.

Korea launched its first OTC oral hair loss drug, dexpanthenol B5. Users discuss its anti-oxidative and anti-inflammatory effects but note a lack of efficacy studies.

The user is unsatisfied with their hair transplant and is considering another transplant, PRP, exosomes, or stem cells. They currently use topical minoxidil, dutasteride, and tretinoin.

Switching from tretinoin to tazarotene with minoxidil led to new hair regrowth after years of maintenance. Tazarotene's selectivity and higher concentration might be more effective for hair growth.

The user is exploring hair growth stimulants other than Minoxidil, mentioning Stemoxydine, various peptides, drugs like Latanoprost and Bimatoprost, and natural remedies such as Rosemary Oil and Caffeine. They express concerns about the long-term effectiveness and safety of these alternatives and seek more information on viable options for hair regrowth.

A peptide-based delivery system for finasteride shows promise in reducing systemic side effects while maintaining hair growth effectiveness. Combining this with other treatments like minoxidil and RU58841 could enhance results with lower systemic absorption.

The conversation discusses the potential of PP405 as a hair loss treatment, with some users expressing skepticism and others hopeful about its development. There is also mention of other treatments like Minoxidil, Finasteride, and Pyrilutamide, with users debating the effectiveness and safety of self-experimentation versus waiting for clinical trial results.

The user switched from oral minoxidil to topical minoxidil and added JXL-069/PP405-3HP, along with topical dutasteride, melatonin, and tretinoin. They also use low-level laser therapy (LLLT) but doubt its effectiveness.

ET-02, a PAI-1 inhibitor, is not proven to be more effective than Minoxidil for hair loss. Other treatments like finasteride, dutasteride, PP405, and AMP-303 are also discussed, focusing on cellular senescence and oxidative stress.

Follicopeptide (FOL005) by Coegin Pharma will launch as a cosmetic hair growth treatment by Q2 2025, showing similar efficacy to finasteride. Users discuss the benefits and skepticism of releasing hair loss treatments as cosmetics rather than drugs.

A user with AGA uses topical spironolactone 2% due to side effects from the oral form and is concerned about its use during conception and breastfeeding. They seek alternatives to prevent AGA relapse while planning pregnancy and after childbirth.

FOL-005 claims to be more effective than Minoxidil and Finasteride but lacks anti-DHT properties, leading to potential reduced efficacy over time. Concerns are raised about misleading marketing and the safety of alternative treatments like Pyrilutamide and Clascoterone.

A 52-year-old male with Multiple Sclerosis is considering using Finasteride and Testosterone Replacement Therapy (TRT) for hair loss but is advised to lose weight first to avoid side effects. He is currently focusing on diet, weight loss, and using Rogaine and microneedling for hair treatment.

A user shared a new hair loss treatment protocol including topical dutasteride, latanoprost, caffeine, minoxidil, tretinoin, and triamcinolone acetonide. Others discussed the effectiveness and availability of these treatments, with some suggesting simpler oral alternatives.

The user has tried various hair loss treatments including topical minoxidil, oral finasteride, oral dutasteride, oral minoxidil, and exosome therapy, but none have been effective. They suspect trichodynia might be preventing these treatments from working.

Crushing spironolactone pills and combining them with minoxidil for topical application may be effective for hair loss, with the addition of finasteride suggested. Adding rosemary and peppermint oils can help mask the unpleasant smell.